(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.23%) $83.66
(-1.16%) $1.619
(0.10%) $2 349.60
(-0.07%) $27.52
(0.25%) $924.40
(0.36%) $0.935
(0.67%) $11.02
(0.14%) $0.800
(-0.07%) $92.11
0.02% $ 172.36
Live Chart Being Loaded With Signals
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases...
Stats | |
---|---|
Dzisiejszy wolumen | 1.91M |
Średni wolumen | 954 093 |
Kapitalizacja rynkowa | 6.57B |
EPS | $0 ( 2024-02-22 ) |
Następna data zysków | ( $0 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -66.29 |
ATR14 | $1.830 (1.06%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-09-26 | Desai Antal Rohit | Sell | 134 | Class A common stock |
2023-09-26 | Desai Antal Rohit | Sell | 993 929 | Class B common stock |
2023-09-26 | Mcgaughy R Kent Jr | Sell | 280 | Class A common stock |
2023-09-26 | Mcgaughy R Kent Jr | Sell | 278 309 | Class B common stock |
2023-09-26 | Mcgaughy R Kent Jr | Sell | 699 | Stock Option (right to buy) |
INSIDER POWER |
---|
-100.00 |
Last 100 transactions |
Buy: 0 | Sell: 4 695 639 |
Wolumen Korelacja
Reata Pharmaceuticals Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
CREX | 0.957 |
MYRG | 0.875 |
ALLR | 0.869 |
MSSA | 0.849 |
SGEN | 0.847 |
NETE | 0.835 |
PLYA | 0.832 |
MHUA | 0.831 |
USAP | 0.83 |
SGTX | 0.825 |
10 Najbardziej negatywne korelacje | |
---|---|
RMGBU | -0.875 |
ENVI | -0.851 |
EJFA | -0.838 |
ONEM | -0.837 |
ESSA | -0.837 |
SVOK | -0.824 |
SAII | -0.819 |
FNCB | -0.818 |
BSBK | -0.816 |
PAIC | -0.814 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Reata Pharmaceuticals Inc Korelacja - Waluta/Towar
Reata Pharmaceuticals Inc Finanse
Annual | 2022 |
Przychody: | $2.22M |
Zysk brutto: | $2.22M (100.00 %) |
EPS: | $-8.59 |
FY | 2022 |
Przychody: | $2.22M |
Zysk brutto: | $2.22M (100.00 %) |
EPS: | $-8.59 |
FY | 2021 |
Przychody: | $11.49M |
Zysk brutto: | $11.49M (100.00 %) |
EPS: | $-8.19 |
FY | 2020 |
Przychody: | $9.02M |
Zysk brutto: | $9.02M (100.00 %) |
EPS: | $-7.35 |
Financial Reports:
No articles found.
Reata Pharmaceuticals Inc
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej